Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Decreases By 6.9%

Aileron Therapeutics, Inc. (NASDAQ:ALRNGet Free Report) saw a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 239,200 shares, a drop of 6.9% from the May 15th total of 256,900 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average trading volume of 92,400 shares, the days-to-cover ratio is currently 2.6 days.

Insider Activity at Aileron Therapeutics

In related news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total transaction of $85,526.15. Following the completion of the sale, the insider now directly owns 1,779,306 shares of the company’s stock, valued at $7,490,878.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total transaction of $85,526.15. Following the completion of the sale, the insider now directly owns 1,779,306 shares of the company’s stock, valued at $7,490,878.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total value of $30,361.50. Following the sale, the insider now directly owns 1,753,156 shares of the company’s stock, valued at $5,697,757. The disclosure for this sale can be found here. Over the last three months, insiders sold 64,618 shares of company stock valued at $248,685. 5.57% of the stock is owned by insiders.

Hedge Funds Weigh In On Aileron Therapeutics

A hedge fund recently raised its stake in Aileron Therapeutics stock. Texas Capital Bank Wealth Management Services Inc lifted its stake in Aileron Therapeutics, Inc. (NASDAQ:ALRNFree Report) by 65.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,171 shares of the company’s stock after acquiring an additional 10,398 shares during the period. Texas Capital Bank Wealth Management Services Inc owned approximately 0.16% of Aileron Therapeutics worth $174,000 at the end of the most recent reporting period. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ALRN has been the subject of a number of recent research reports. LADENBURG THALM/SH SH raised their target price on Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Brookline Capital Management raised Aileron Therapeutics to a “strong-buy” rating in a research report on Thursday, May 30th.

Read Our Latest Analysis on Aileron Therapeutics

Aileron Therapeutics Price Performance

NASDAQ:ALRN opened at $3.12 on Wednesday. Aileron Therapeutics has a 1 year low of $1.01 and a 1 year high of $7.42. The business has a fifty day simple moving average of $4.00 and a two-hundred day simple moving average of $4.31. The company has a market capitalization of $67.36 million, a P/E ratio of -0.98 and a beta of 2.11.

Aileron Therapeutics (NASDAQ:ALRNGet Free Report) last posted its quarterly earnings results on Monday, May 20th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.72). As a group, analysts anticipate that Aileron Therapeutics will post -0.93 earnings per share for the current year.

About Aileron Therapeutics

(Get Free Report)

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Recommended Stories

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.